BACKGROUND: Oral mucositis (OM)-related pain affects most patients with head and neck cancer during treatments, but its management is not standardized. METHODS: We retrospectively collected data about the opioid therapy used for OM-induced pain in all patients with oropharyngeal cancer treated with chemoradiotherapy (CRT) between 2009 and 2013. To compare the different opioids, a conversion into oral morphine equivalent daily dose (OMEDD) was performed. The highest OMEDD (h-OMEDD) and the opioids' weekly increase were associated with patient, tumor, or treatment-related characteristics in order to identify predictive factors of opioid consumption. RESULTS: Ninety-seven percent of patients received opioids. The h-OMEDD was significantly correlated with a higher OM-grade and a lower smoking history. The weekly opioids' increase was higher in patients with lower smoking history and human papillomavirus (HPV) positivity. CONCLUSION: Opioid therapy remains the mainstay for OM-related pain management during CRT. The role of previous smoking and HPV on opioid use needs further confirmations.
BACKGROUND:Oral mucositis (OM)-related pain affects most patients with head and neck cancer during treatments, but its management is not standardized. METHODS: We retrospectively collected data about the opioid therapy used for OM-induced pain in all patients with oropharyngeal cancer treated with chemoradiotherapy (CRT) between 2009 and 2013. To compare the different opioids, a conversion into oral morphine equivalent daily dose (OMEDD) was performed. The highest OMEDD (h-OMEDD) and the opioids' weekly increase were associated with patient, tumor, or treatment-related characteristics in order to identify predictive factors of opioid consumption. RESULTS: Ninety-seven percent of patients received opioids. The h-OMEDD was significantly correlated with a higher OM-grade and a lower smoking history. The weekly opioids' increase was higher in patients with lower smoking history and human papillomavirus (HPV) positivity. CONCLUSION: Opioid therapy remains the mainstay for OM-related pain management during CRT. The role of previous smoking and HPV on opioid use needs further confirmations.
Authors: Janet H Van Cleave; Mei R Fu; Antonia V Bennett; Catherine Concert; Ann Riccobene; Anh Tran; Allison Most; Maria Kamberi; Jacqueline Mojica; Justin Savitski; Elise Kusche; Mark S Persky; Zujun Li; Adam S Jacobson; Kenneth S Hu; Michael J Persky; Eva Liang; Patricia M Corby; Brian L Egleston Journal: Mhealth Date: 2021-01-20
Authors: Sondos Zayed; Cindy Lin; R Gabriel Boldt; Jinka Sathya; Varagur Venkatesan; Nancy Read; Lucas C Mendez; Dwight E Moulin; David A Palma Journal: Adv Radiat Oncol Date: 2020-10-26
Authors: Stine Mogensen; Charlotte Treldal; Claus A Kristensen; Jens Bentzen; Louise Lawson-Smith; Janne Petersen; Ove Andersen Journal: Pain Rep Date: 2017-08-23